Innate Pharma (IPHA) Current Deferred Revenue (2017 - 2025)

Innate Pharma (IPHA) has reported Current Deferred Revenue for 9 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

• Quarterly Current Deferred Revenue rose 358.6% year-over-year to $3.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 million (up 358.6% YoY) and the FY2025 annual result came in at $3.2 million, up 358.6% from the prior year.
• Current Deferred Revenue grew to $3.2 million in Q4 2025 per IPHA's latest filing, from $640668.3 in the prior quarter.
• Over the last five years, Current Deferred Revenue for IPHA reached as high as $83.2 million in Q2 2022 and fell as low as $640668.3 in Q2 2025.
• A 5-year average of $29.2 million and a median of $10.8 million in 2021 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2021 — Current Deferred Revenue slumped 99.87% — and 2025, when it surged 358.6%.
• Year by year, Current Deferred Revenue stood at $14.2 million in 2021, then plunged by 47.52% to $7.5 million in 2022, then declined by 10.59% to $6.7 million in 2023, then sank by 89.5% to $700979.8 in 2024, then soared by 358.6% to $3.2 million in 2025.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $3.2 million, $640668.3, and $700979.8 for Q4 2025, Q2 2025, and Q4 2024 respectively.